An update on adenosine A2A receptors as drug target in Parkinson's disease by Vallano Ferraz, Antonio et al.
Vallano et al. 2011                                                                                                                                            A2AR & Parkinson’s disease   
AN UPDATE ON ADENOSINE A2A RECEPTORS AS DRUG TARGET IN 
PARKINSON’S DISEASE 
 
 
Antoni Vallano1, 2, Víctor Fernández-Dueñas2, Consuelo Pedrós1, 2, Josep María 
Arnau1, 2 & Francisco Ciruela2 
 
1Servei de Farmacologia Clínica, Hospital Universitari de Bellvitge-ICS, IDIBELL. 2Unitat 
de Farmacologia, Departament Patologia i Terapèutica Experimental, Facultat de Medicina, 
Universitat de Barcelona, L’Hospitalet de Llobregat, 08907 Barcelona, Spain.  
 
Running title: A2AR & Parkinson’s disease 
 
 
Number of pages: 37 
Abstract:  199 words 
Main text: 4269 words   
References: 67 references 
Fig. legends:   131 words 
 
 
Corresponding author: Francisco Ciruela, Ph.D. 
    University of Barcelona 
    Unitat de Farmacologia 
    Dept. de Patologia i Terapeutica Experimental 
    Facultat de Medicina (Campus de Bellvitge) 
    Pavelló de Govern, Av. Feixa Llarga, s/n   
    08907 L'Hospitalet del Llobregat, Barcelona, Spain 
    Tel: +34 (93) 402 4280/ +34 (93) 403 5820  
    Fax: +34 (93) 402 9082 
    E-mail: fciruela@ub.edu  
 
 
Keywords: Adenosine A2A receptors; Parkinson’s disease; GPCR oligomerization; 
Clinical trial; Istradefylline; Preladenant. 
Vallano et al. 2011                                                                                                                                   A2AR & Parkinson’s disease  
  2
Abstract  
Adenosine receptors are G protein-coupled receptors (GPCRs) that mediate the 
physiological functions of adenosine. In the central nervous system adenosine A2A 
receptors (A2ARs) are highly enriched in striatopallidal neurons where they form 
functional oligomeric complexes with other GPCRs such us the dopamine D2 receptor 
(D2R). Furthermore, it is assumed that the formation of balanced A2AR/D2R receptor 
oligomers are essential for correct striatal function as the allosteric receptor-receptor 
interactions established within the oligomer are needed for properly sensing adenosine 
and dopamine. Interestingly, A2AR activation reduces the affinity of striatal D2R for 
dopamine and the blockade of A2AR with specific antagonists facilitates function of the 
D2R. Thus, it may be postulated that A2AR antagonists are pro-dopaminergic agents. 
Therefore, A2AR antagonists will potentially reduce the effects associated with dopamine 
depletion in Parkinson’s disease (PD). Accordingly, this class of compounds have 
recently attracted considerable attention as potential therapeutic agents for PD 
pharmacotherapy as they have shown potential effectiveness in counteracting motor 
dysfunctions and also displayed neuroprotective and anti-inflammatory effects in animal 
models of PD. Overall, we provide here an update of the current state of the art of these 
A2AR-based approaches that are under clinical study as agents devoted to alleviate PD 
symptoms. 
. 
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INTRODUCTION  
Adenosine is a nucleoside which is mainly regarded as a retaliatory metabolite [1], thus it 
increases oxygen supply and decreases oxygen consumption. Consequently, adenosine 
potentially regulates a large amount of physiological processes (i.e. respiratory 
regulation, hormone action, neural function, platelet aggregation, lymphocyte 
differentiation and vascular tone). In addition, adenosine exerts a negative chronotropic 
and dromotropic effect on the heart, as well as it mediates inhibition of neurotransmitter 
release and lipolysis. In the central nervous system (CNS), adenosine acts principally as a 
negative neuromodulator for example decreasing striatal dopamine and glutamate release. 
In the brain, adenosine is produced by metabolism of adenosine triphosphate (ATP) when 
it is co-released with glutamate from nerve terminals and astrocytes [2]. Also, 
extracellular adenosine is related to the intracellular concentration of adenosine and 
nucleotides, such as ATP, adenosine monophosphate (AMP) and cyclic adenosine 
monophosphate (cAMP) [3]. In fact, in some brain areas, like the hippocampus, most of 
the extracellular adenosine seems to depend mainly on intracellular adenosine, the 
concentration of which is related to the rate of breakdown and synthesis of ATP [3]. 
Thus, adenosine would be released as a neuromodulator [4] by the effector cells in 
response to an increased metabolic demand [5]. Interestingly, in the striatum, it has been 
suggested that the main source of extracellular adenosine is intracellular cAMP [6]. Thus, 
since cAMP can only be generated by the action of the enzyme adenylyl cyclase, striatal 
extracellular adenosine would mostly reflect an increased activation of metabotropic 
receptors positively coupled to cAMP as a second messenger, for example the dopamine 
D1 receptor. In addition, the dynamics of adenosine release in the cerebellum has been 
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recently characterized by means of adenosine biosensors. Interestingly, by using this 
experimental approach it has been possible to demonstrate that adenosine release shares 
many characteristics of conventional neurotransmitter liberation such as a dependence on 
action potential width and homosynaptic plasticity [7]. 
Adenosine mediates its actions through activation of specific G protein-coupled receptors 
(GPCRs). Four subtypes of adenosine receptors (ARs) have been identified so far, 
namely A1R, A2AR, A2BR and A3R, all of them bearing a distinctive pharmacological 
profile, tissue distribution and effector coupling [6]. Thus, while A1R are coupled to Gi/o, 
A2AR are coupled to Gs/olf receptors. Interestingly, in the CNS the effects of adenosine are 
mainly mediated by A1Rs and A2ARs [8]. Hence, while A1Rs are more widespread in the 
brain the A2ARs are highly concentrated in the striatum where they show both presynaptic 
and postsynaptic localization in γ-aminobutyric acid (GABA)-containing neurons 
(GABAergic neurons) [9]. Interestingly, presynaptic A2AR form heteromers with the A1R 
in the glutamatergic terminals and it is believed that these heteromers act as 
concentration-dependent processors that exert subtle modulation of glutamate release 
[10]. Conversely, the postsynaptic A2AR simultaneously heteromerize with the dopamine 
D2 receptor (D2R) and the metabotropic glutamate type 5 (mGlu5) receptor forming 
higher-order oligomers or receptor mosaics (or RMs) in the dendritic spine of 
enkephalinergic GABAergic medium spiny neurons (MSN) [11]. Interestingly, the 
A2AR/D2R/mGlu5 receptor oligomeric complex, which is located extrasynaptically and 
adjacent to the glutamatergic synapse of the dendritic spine of MSNs, is activated by 
volume transmission and the receptor cross-talk within the complex helps to modulate 
postsynaptic plastic changes at the glutamatergic synapse [10]. Overall, GPCR 
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oligomerization brings new and exciting possibilities to the therapy of PD, since 
combined therapies acting at a named oligomer can have very different pharmacological 
effects from the ones expected through the monomers. Thus, the desired effect, e.g. the 
antiparkinsonian effect, can be mediated by the integrated activation of multiple effector 
systems but also by the allosterism or cross-talk mechanisms provided by the activation 
of the receptor monomers within the oligomer. Consequently, the existence of adenosine 
receptors containing oligomers in the striatum allows a much more elaborate tuning of 
the regulation of both presynaptic and postsynaptic neuronal responses in local striatal 
circuitry (Fig. 1A). 
 
Neurobiology of Parkinson’s disease 
Parkinson’s disease (PD) is a progressive systemic neurodegenerative disorder associated 
with, but not only, the loss of dopaminergic nigrostriatal neurons and is recognized as one 
of the most common neurological disorders, affecting approximately 1% of individuals 
over the age of 60. While the initial symptoms within the pre-motor phase may be 
nonspecific (i.e. fatigue, depression, constipation, decreased sense of smell and sleep 
problem) the associated features and clinical signs at the motor phase include resting 
tremor, rigidity, bradykinesia, and postural instability. Unfortunately, as a 
neurodegenerative disease, the motor phase of this pathology continues to progress late in 
the disease to affect other brain areas (i.e. cortex), thus patients may then exhibit 
cognitive dysfunction and dementia [12]. 
The major neuropathologic findings underlying the clinical symptoms of PD is the loss of 
pigmented dopaminergic neurons located in the pars compacta of the substantia nigra 
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(SNpc) [13]. However, some studies indicate that the loss of dopaminergic neurons 
occurs after there is significant loss and pathology of other brain regions including the 
locus coeruleus (LC), nucleus basalis of Meynert, dorsal raphe nucleus and the dorsal 
motor nucleus of the vagus [14, 15], and there is no explanation for this neuronal 
selection. In addition, a further neuropathological hallmark of PD is the existence of 
cytoplasmic proteinaceous inclusion bodies, called Lewy bodies, and dystrophic neurites, 
designated Lewy neurites [13], a feature common to other types of Parkinsonism. 
Interestingly, both Lewy bodies and Lewy neurites enclose a mixture of proteins, but α-
synuclein seems to be the main structural component [16]. Unfortunately, 60-80% of 
dopaminergic neurons are lost before the motor signs of PD emerge (pre-clinical phase). 
This fact points out the relevance of finding a biomarker of the pathology, especially for 
early stages of the disease. 
The basal ganglia, which includes the SN, modulates the cortical output necessary for 
normal movement. Inhibitory output to the thalamocortical motor circuit is directed from 
the globus pallidus pars interna (GPi) and the substantia nigra pars reticulata (SNr) in the 
basal ganglia where it acts to suppress movement. Accordingly, within the basal ganglia 
two major pathways exist and are referred to as the direct and indirect pathways (Fig. 
1A), with a third hyperdirect excitatory corticosubthalamic pathway. Dopamine released 
by neurons of the substantia nigra pars compacta (SNc) acts on the striatum via activation 
of either dopamine D1R or D2R subtypes. These receptors are distributed across two main 
populations of GABAergic MSNs, one that contains the neuropeptides dynorphin (DYN) 
and substance P (SP) and the other containing enkephalin (ENK) [17, 18]. It is generally 
accepted that striatal DYN/SP-expressing neurons, also containing D1R, constitute the 
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direct pathway and project to the GPi/SNr (Fig. 1A). On the other hand, striatal ENK-
expressing neurons containing D2R are part of the indirect pathway (Fig. 1A). However, a 
distinct population of MSNs with a unique phenotype, namely that co-expressing both 
DYN and ENK and also the D1R and the D2R, have been recently described [19]. The 
role of these D1R/D2R-DYN/ENK neurons, which are highly expressed in the nucleus 
accumbens (NAc) core and shell but with very low expression in the caudate-putamen 
(CPu), remains to be elucidated.  
In normal non-pathological conditions, dopamine released by the SNc activates the direct 
pathway and inhibits the indirect pathway resulting in net inhibition of the GPi/SNr, thus 
resulting in a greater activity of the thalamocortical system that facilitates movements, 
and cognitive and behavioural outputs. However, in PD, because the loss of 
dopaminergic neurons in the SNc, striatal dopamine is reduced and inhibition of the 
GPi/SNr decreases. Thus, disinhibition of the GPi/SNr leads to increased inhibitory 
output to the thalamus which suppresses movement (Fig. 1B). As a result, the central role 
that the striatum plays in processes such as motor activity control, motor learning and 
some forms of associative and visual learning [20] is altered. Overall, dopaminergic 
neurons from the SNc control the direct and indirect pathways within the basal ganglia 
via activation of dopamine D1R or D2R. And, as described above, an interaction of 
dopamine receptors with glutamate and adenosine receptors in the same striatal neurons 
has been demonstrated, thus drugs acting on the latter group of receptors have been 
postulated as therapeutic tools in PD as they can modulate dopaminergic 
neurotransmission [21]. Furthermore, these receptor-receptor interactions highlight the 
potential role of the oligomers formed by these GPCRs as new therapeutic targets, since a 
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multimodal drug-approach would lead restore normal function in pathological states such 
as  PD [21].  
 
The treatment of PD: the rationale for using adenosine A2AR antagonists 
The treatment of PD comprises mainly pharmacotherapy, although surgical interventions 
(i.e. deep brain stimulation) are also in use. However, all surgical procedures have 
associated risks and surgery is not suitable for everyone, typically only for advanced PD 
refractory to pharmacotherapy. Research around gene therapy and stem cell therapy is 
also promising but remains much underdeveloped thus far. So, at the moment the 
applications of these new therapies are still unknown. Therefore, the best management for 
most people with PD remains to be pharmacological treatments. 
The vast majority of PD pharmacological treatments seek to restore dopamine signalling 
and thus to diminish the intensity of the motor and non-motor symptoms. Since the sixties 
the most effective therapy for the management of this disease is based on the use of drugs 
that mimic dopamine, initially the precursor L-DOPA (L-3,4-dihydroxyphenylalanine)  
[22] and later on other dopaminergic agents, which act to compensate for the loss of this 
neurotransmitter. For instance, other dopaminergic approaches include inhibition of 
dopamine turnover using monoamine oxidase type B (MAO-B) inhibitors (i.e. selegiline 
and rasagiline) [23], catechol O-methyl-transferase (COMT) inhibitors (i.e. entacapone 
and tolcapone) [24, 25] and dopamine receptor agonists (i.e. ergot D2R agonists: 
bromocriptine, pergolide, cabergoline; and non-ergot D2R agonists: pramipexole, 
ropinirole, rotigitine) (for review see [26]). Interestingly, although L-DOPA has been 
proved very efficacious in the treatment of PD symptoms, long term treatment can result 
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in a loss of efficacy as motor functions deteriorate and the disease progresses. In addition, 
the appearance of motor complications such as dyskinesia and non-motor complications 
including psychosis and impulse-control disorders become more severe and problematic 
with continued treatment [27]. Thus, as PD progresses, fewer dopamine neurons are 
available to store and release L-DOPA-derived dopamine, and the patient's clinical status 
begins to fluctuate more and more closely in accordance with plasma L-DOPA levels. 
Exposing striatal dopamine receptors to fluctuating dopamine concentrations may cause a 
hypersensitivity that is expressed clinically as peak-dose dyskinesia. Finally, fluctuating 
L-DOPA-derived dopamine concentrations in association with the advancement of the 
disease may be responsible for the development of motor fluctuations and dyskinesia. 
As mentioned above, the dopamine-based agents used in PD therapy have significant 
limitations, a fact that has forced the researchers to explore new non-dopaminergic PD 
treatments that circumvent these problems. Consequently, research is nowadays focused 
on finding better pharmacological therapies that provide efficacious relief of parkinsonian 
symptoms while evoking less risk of dyskinesia and associated motor-complications. 
Interestingly, another important area of research associated to these non-dopaminergic-
based PD drugs is related to the neuroprotection of the dopaminergic neurons and other 
neuronal types (i.e. brain stem and LC neurons), in order to slow down the progression of 
the disease, but unfortunately still no neuroprotective therapy exists. Accordingly, we 
will delineate here some in vivo studies revolving around neuroprotection (i.e. protection 
of surviving neurons) and we will leave aside those related to neurorestoration (i.e. return 
to functioning phenotype of quiescent neurons) as the latter issue may constitute a review 
into itself [28, 29]. 
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As introduced above, a promising treatment for the disease is based on the modulation of 
dopaminergic neurotransmission by means of an indirect action towards dopamine 
receptors. These non-dopaminergic-based PD therapies may offer advantages over 
dopamine medications, possibly including fewer side effects. Interestingly, one non-
dopaminergic approach that has received considerable attention by the scientific 
community is the modulation exerted by adenosine receptors in general and by the A2AR 
in particular on the dopaminergic neurotransmission. Adenosine, as a neuromodulator, 
synchronizes responses to several neurotransmitters including dopamine in brain areas 
that are important for motor function, mood, and learning and memory [3]. Interestingly, 
it has been recently described that the D2R interacts with the A2AR and the mGlu5 
receptor in striatopallidal GABAergic neurons [11], in such a manner that A2AR and 
mGlu5 receptor agonists act synergistically to reduce the affinity of D2R agonist binding 
sites [30]. In addition, by using the novel resonance energy transfer technique SRET [31] 
and through bimolecular fluorescence complementation techniques the existence of 
D2R/A2AR/mGlu5 receptor oligomer in living cells has recently been demonstrated [11]. 
Moreover, coimmunoprecipiation studies in rat striatal tissue have confirmed this 
interaction [11]. Interestingly, in striatopallidal GABAergic neurons, it has been 
demonstrated that D2R/A2AR dimerization results in a reciprocal inhibition and in a final 
negative outcome in the cAMP- and phospholipase C-mediated signalling [32]. Thus, 
A2AR blockade facilitates D2R signalling and thereby might in theory restore D2R-
mediated striatal neurotransmission. Overall, the presence of the D2R/A2AR/mGlu5 
receptor oligomeric complex and the cross-talk within the receptor heteromer might help 
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to modulate postsynaptic plasticity at the glutamatergic synapse, and thus the output of 
striatopallidal GABAergic neurons (Fig. 1).  
Increased knowledge about oligomerization has helped scientist to the design and 
development of specific A2AR antagonists for the treatment of PD [33].  Interestingly, the 
obtained preclinical data suggest that these A2AR antagonist (i.e. istradefylline) might 
have major applications in the treatment of PD: a) providing motor benefit as 
monotherapy; b) potentiating the benefit of dopamine agonists and allowing a lowering of 
L-DOPA dose; c) preventing the development of L-DOPA induced dyskinesias (LID), 
and; d) allowing the maintenance of the motor response with less dyskinesia using a 
lower L-DOPA dose [34]. Indeed, A2AR antagonists have been shown to possess 
antiparkinsonian properties in human PD patients with LID [35]. This antiparkinsonian 
effect is probably due to the action of the A2AR antagonist at A2AR/D2R oligomers, 
thereby reducing the A2AR-mediated inhibition of D2R signalling. Furthermore, the status 
of some oligomers might be altered in pathological situations such as PD or LID. In line 
with this, the appearance of LID has been suggested to be due to the dominance of 
A2AR/A2AR homodimers versus A2AR/D2R heterodimers and D2R/D2R homodimers, thus 
with an uncontrolled increment in the A2AR signalling [36]. Indeed, the expression of 
A2AR has been shown to be increased in the brain of PD patients with dyskinesias and it 
has been postulated that the increased synthesis of A2ARs in striatopallidal pathway 
neurons is associated with the development of dyskinesias following long-term L-DOPA 
therapy in PD [37]. Interestingly, this hints at another potential therapeutical use of A2AR 
antagonists in PD, namely their use not only as anti-parkinsonian agents in patients with 
pre-existing LID but also its use de novo in combination with dopaminergic agents to 
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prevent the development of dyskinesias [38].[39] Recently, the availability of A2ARs in 
PD patients with and without LIDs was investigated by using positron emission 
tomography (PET) scan and the [11C]SCH442416 compound [40]. Interestingly, while 
the thalamic A2AR availability was similar in PD subjects with and without LIDs (and 
similar to the control subjects) the A2AR binding in the CPu of PD subjects with LIDs 
was significantly increased when compared to the PD subjects without LIDs [40]. 
Overall, as patients with PD with LIDs show increased A2AR expression in the striatum, 
and thus altered adenosinergic transmission in this brain region, it sounds reasonable to 
start thinking in clinical trials using A2AR antagonists for the treatment of these motor 
complications. 
As mentioned earlier, another important issue around the research related to PD concerns 
the direct neuroprotection of the dopaminergic neurons in order to slow down the 
progression of the disease. Interestingly, A2AR antagonism or gene KO has been found to 
be neuroprotective in different models of neurodegeneration, such as Alzheimer’s 
disease, Huntington’s disease, and cerebral ischemia [41-44]. Indeed, in preclinical 
studies using an animal model of PD (i.e. the subchronic MPTP mouse model) it was 
shown that the concomitant treatment with SCH58261, an A2AR antagonist, attenuated 
dopamine cell loss and gliosis in the SNc and in the striatum [45]. In brief, the SCH58261 
injected half an hour before MPTP administration, and keep after MPTP treatment 
discontinuation, prevented the degeneration of nigrostriatal TH positive neurons [45]. 
Also, the selective deletion of neuron-specific forebrain A2AR prevented MPTP-induced 
dopamine neuron degeneration and glial activation [45]. Recently, another A2AR 
antagonist, the ST1535, showed a neuroprotective and anti-inflammatory effect in the 
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same animal model [39]. Collectively, these results provide evidence of the key role 
played by the blockade of A2AR in PD neuroprotection. Overall, with the described 
neuroprotective effect on dopaminergic neuron toxicity the A2AR antagonists have 
opened new prospects as symptomatic antiparkinsonian drugs, and thus justifyied the 
implementation of clinical trials studying the benefit of using these kinds of drugs early 
in the treatment of PD. 
 
Clinical evaluation of adenosine A2AR antagonists in PD 
From the wide-range of non-dopaminergic drugs targeted at the management of PD (for 
review see [46]), we will focus here particularly on the clinical efficacy and the described 
outcomes of the A2AR-based approaches that are in at least phase II clinical development 
for the treatment of PD. Interestingly, several preclinical studies point to the benefits of 
adenosine A2AR antagonists on the symptomatic management of PD [47-50]. 
Accordingly, selective adenosine A2AR antagonists, such as istradefylline (KW-6002), 
preladenant (SCH-420814), vipadenant (BIIB014), SYN115 and ST-1535, are being 
assessed in clinical studies as potential antiparkinsonian drugs [46, 51, 52]. Thus, we will 
describe here, as a prototypical A2AR-based antiparkinsonian agent, the development of 
the selective adenosine A2AR antagonist istradefylline, which is the first selective 
adenosine A2AR antagonist well studied in preclinical studies and clinical trials. 
Istradefylline was originally assessed as monotherapy and adjunctive therapy in rodent 
and primate models of PD, thus the obtained preclinical data suggested that this A2AR 
antagonist may have major applications in the management of PD[53-58]. Accordingly, it 
was initially proposed that istradefylline might provide motor benefits as monotherapy 
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and also it was postulated that it may potentiate the benefit of dopamine agonists. Hence, 
the combined use of istradefylline with L-DOPA would allow lowering L-DOPA doses 
used in PD therapy and thus it would be prevented, in theory, the development of LID 
(i.e. maintenance of the motor response with less dyskinesia using a lower L-DOPA 
dose) [34]. Therefore, with these encouraging preclinical data, clinical effects of 
istradefylline were studied in human beings [59].  
Firstly, regarding data from population pharmacokinetic analysis of istradefylline in 
healthy volunteers and patients with PD it was shown the drug fits to a two-compartment 
model with first order absorption. Thus, in clinical pharmacokinetics studies, the terminal 
elimination half life of istradefylline was of 70 to 118 hours, with a peak time of 2 to 5 
hours. Istradefylline inhibits and is primarily metabolized by cytochrome P450 3A4 
(CYP3A4) and is also an inhibitor of the efflux transporter P-glycoporotein. Smoking and 
CYP3A4 inhibitors as concomitant drugs alter istradefylline clearance and systemic 
exposure. As a result, istradefylline area under the concentration-time curve at steady-
state increased 35% in the presence of CYP3A4 inhibitors and decreased 38% in smokers 
[60].      
The clinical effects of istradefylline were evaluated in multicentre double-blind, placebo-
controlled randomised clinical trials involving patients with moderate or advanced PD 
[35, 61-65][63], while only in one clinical trial the effects of treatment were examined in 
patients with early PD [66] (Table 1). To briefly summarize, the length of the studies was 
short (12 weeks) (Table 1). The mean age of patients included in clinical trials ranged 
from 63 to 65 years old and approximately 60% were men, while the mean time since 
diagnosis of disease was from 8 to 10 years (Table 2). The clinical trials evaluated a wide 
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range of istradefylline doses (from 5 to 80 mg), but the most studied doses were 20 and 
40 mg (Table 1). On the other hand, patients were usually treated with L-DOPA (mean 
daily dosage from 400 mg to 857 mg) (Table 2), and often also with other concomitant 
antiparkinsonian medications (Table 2), while only in one clinical trial patients were 
treated neither with L-DOPA nor with other dopaminergic drugs (Table 1). The mean 
time since onset of motor complications of patients was 3 years and the mean time spent 
by patients in the “off” state was 6 hours (Table 2). Finally, drugs were generally well 
tolerated in all the clinical trials mentioned above. Thus, on average, 88 % of subjects in 
each group (i.e. istradefylline and placebo) completed double-blind treatment when all 
istradefylline clinical trials were analyzed (853 out of 968 istradefylline treated patients 
and 435 out of 491 placebo treated patients), while about only 11-12% of drug-treated 
patients discontinued prematurely the treatment (115 out of 968 istradefylline treated 
patients and 56 out of 491 placebo treated patients). The most common reasons (~50%) 
for discontinuing treatment were the adverse events (61 out of 115 istradefylline 
discontinued patients and 27 out of 56 placebo discontinued patients), followed by 
withdraw consent (16.5% in istradefylline discontinued patients and 25% in placebo 
discontinued patients), lack of efficacy (7.7% in istradefylline discontinued patients and 
19.6% in placebo discontinued patients), non-compliance or protocol violation (13% in 
istradefylline discontinued patients and 7% in placebo discontinued patients) and other 
reasons (8.7% in istradefylline discontinued patients and 1.8% in placebo discontinued 
patients). 
The clinical trials evaluating istradefylline efficacy targeted symptoms associated with 
dopamine replacement and therapy of dyskinesia. The most evaluated primary variable 
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for assessing clinical efficacy in clinical trials was the change in time spent on “off” state 
from baseline to end point. The typical primary endpoint was the change from baseline at 
end point in the clinical rating scale of disease Unified Parkinson’s Disease Rating Scale 
(UPDRS) part III subscale [66] (Table 1). Needless to say, available data on the outcomes 
are difficult to interpret. However, in clinical trials, istradefylline reduced the time spent 
in the “off” state in L-DOPA-treated PD patients with motor complications but the 
magnitude of the drug effect was small and with doubtful clinical significance (Table 3). 
In addition, most studies did not reported significant benefit of istradefylline on 
parkinsonian symptoms as measured by the UPDRS, with the exception of a Japanase 
clinical trial (Table 3). In the Mizuno et al study, the UPDRS part III subscale score on 
state was reduced by 5.7 at endpoint in both istradefylline groups (20 and 40 mg) and 3.7 
in the placebo group (Table 3) [65]. Thus, the differences between the two istradefylline 
groups and placebo were statistically significant, but again the relatively modest 
improvement with istradefylline (only 2 points on a scale with a total of 68 points) raised 
the question of clinical relevance. On the other hand, istradefylline as monotherapy in 
patients with early PD was not effective in improving motor symptoms [66] (Table 3). 
With regard to treatment-related adverse events, they were reported in between 59% and 
89% (average of 68.4%) of subjects receiving istradefylline and between 56% and 86% 
(average of 67.6%) of subjects receiving placebo. Globally, the frequency of adverse 
events was not different between groups of patients treated with doses of 20 mg and those 
treated with doses of 40 mg. On the other hand, adverse events caused discontinuation of 
the treatment in 6% of the patients, and were severe in almost 4% of patients treated with 
istradefylline and 2% of the placebo-treated. Finally, the most frequently reported 
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treatment-related adverse events in patients receiving istradefylline were nervous system-
, gastrointestinal-, psychiatric- and respiratory disorders. In particular, dyskinesia, 
dizziness, nausea, constipation and hallucinations were the most frequently reported 
events (Table 4). Overall, a lot of effort has been put in the study of this first adenosine 
A2AR-based drug designed for the treatment of PD and yet the results are modest.   
Interestingly, a new set of A2AR-based antiparkinsonian agents are under study. For 
instance, a phase II, double-blind, placebo-controlled randomised trial that assessed 
efficacy and safety of preladenant in 253 patients with PD and motor fluctuations who 
were receiving L-DOPA and other antiparkinsonian drugs, found significant although 
slight changes in mean daily “off” time when comparing the effects of the selective 
adenosine A2AR antagonist with placebo [67]. On the other hand, the most common 
adverse events in the combined preladenant group versus placebo were similar -i.e. 
somnolence (10% vs. 6%), dyskinesia (9% vs. 13%), nausea (9% vs. 11%), constipation 
(8% vs. 2%), and insomnia (8% vs. 9%). Again, although initial results show that these 
drugs are safe and well tolerated, its efficacy in PD patients has yet to be shown 
conclusive. 
 
FUTURE CHALLENGES 
A2AR antagonists remain one of the most attractive potential non-dopaminergic classes of 
drugs for the management of PD as they have shown effectiveness in counteracting 
parkinsonian motor symptoms and have also displayed potential neuroprotective and anti-
inflammatory effects in animal models of PD. However, the translation of these 
promising pre-clinical observations into benefit in PD patients has yet to be conclusively 
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demonstrated. Thus, the continued optimisation of new symptomatic A2AR-based 
treatments for many of the motor and non-motor problems of PD is required. 
Interestingly, a new generation of A2AR antagonists is now under development. 
Accordingly, there are several phase II and III ongoing clinical trials evaluating the 
efficacy and safety of new selective A2AR antagonist drugs in patients with PD (Table 8). 
Finally, it is important to mention that key to success in this endeavour is the 
improvement of translation of preclinical findings into phase II and III endpoints through 
better clinical study designs employing appropriate study populations. Overall, the need 
for alternative pharmacotherapies in PD is progressively clearer and non-dopaminergic 
drugs such as A2AR antagonists constitute a realistic opportunity to reach this end. 
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ABBREVIATIONS 
A1R = adenosine A1 receptor 
A2AR = adenosine A2A receptor 
ATP = adenosine triphosphate 
cAMP = cyclic adenosine monophosphate 
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CNS = central nervous system 
CPu = caudate-putamen 
CYP3A4 = cytochrome P450 3A4 
D1R = dopamine D1 receptor 
D2R = dopamine D2 receptor 
DYN = dynorphin 
ENK = enkephalin 
GABA = γ-aminobutyric acid 
GPCR = G protein-coupled receptor 
GPi = globus pallidus pars interna 
LC = locus coeruleus  
L-DOPA = L-3,4-dihydroxyphenylalanine 
LID = L-DOPA induced dyskinesias 
mGlu5 = metabotropic glutamate type 5 receptor 
MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MSN = GABAergic medium spiny neurons 
NAc = nucleus accumbens 
PD = Parkinson’s disease 
SN =  substantia nigra 
SNc = substantia nigra pars compacta  
SNr = substantia nigra pars reticulata 
SP =  substance P 
UPDRS = Unified Parkinson’s Disease Rating Scale 
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FIGURE LEGENDS 
Fig. 1. Scheme of the basal ganglia circuitry and its connection to the 
thalamocortical circuit in both normal (A) and PD (B) conditions. Dopaminergic 
neurons from the substantia nigra pars compacta (SNc) control the direct and indirect 
pathways within the basal ganglia via activation of D1R or D2R. Thus, the striatum is 
linked to substantia nigra pars reticulata and globus pallidus pars interna complex (SNr–
GPi) via direct (striatonigral) and indirect (striatal–pallidal–subthalamic–nigral) 
pathways. The co-localisation of receptors for dopamine, glutamate and adenosine in the 
same striatal neurons puts into relevance the potential role of oligomers formed by these 
GPCRs and postulated the use of striatal glutamate and adenosine receptors as therapeutic 
targets in PD. GPe: globus pallidus pars externa; STN: subthalamic nucleus; ENK: 
enkephalinergic neuron; DYN: dynorphinergic neuron. 
Vallano et al. 2011                                                                                                                                   A2AR & Parkinson’s disease  
  21
Table 1. Randomised clinical trials with istradefylline in Parkinson’s disease (PD) 
Authors (year) 
Study 
Country/ies 
Phase and 
Design clinical 
trial 
Patients 
 
Treatment 
(drugs, doses 
and length) 
Primary  
outcome 
Other 
outcomes 
Bara-Jimenez et 
al 
(2003) 
USA 
[61] 
 
●Proof-of 
principle 
●Double-blind, 
placebo-
controlled 
randomised trial  
(randomisation 
ratio 3:1) 
15 subjects with 
moderate to 
advanced PD 
 
●Istradefylline  
40 mg/day oral 
vs. placebo 
●Istradefylline 
80 mg/day oral 
vs. placebo 
→6 weeks 
●Exploratory 
study 
●No primary 
efficacy variable 
was defined. 
●UPDRS III 
motor scale 
scores 
●Dyskinesia 
scales 
●Duration of 
LD action  
●Adverse events 
Hauser et al 
(2003) 
US-001 Study 
USA 
[62] 
●Phase II 
●Multicentric 
double-blind, 
placebo-
controlled  
randomised  
trial  
(randomisation 
ratio 1:1:1)   
83 LD treated 
patients with 
motor 
fluctuations and 
dyskinesias 
 
●Istradefylline 
5/10/20 mg/day 
oral  
vs. placebo 
●Istradefylline 
10/20/40 
mg/day oral  
vs. placebo 
→12 weeks  
●Exploratory 
study. 
●No primary 
efficacy variable 
was defined. 
●Off time 
●On time with 
dyskinesia 
●UPDRS scores   
●Dyskinesia 
scales 
●Adverse events 
LeWitt et al 
(2008) 
6002-US-005 
Study 
USA, Canada 
[35] 
●Phase III 
●Multicentric 
double-blind, 
placebo-
controlled  
randomised trial 
(randomisation 
ratio 2:1) 
196 LD subjects 
with PD 
experiencing 
prominent 
wearing-off 
motor 
fluctuations 
 
●Istradefylline 
40 mg per day 
oral  vs. placebo 
→12 weeks  
 
 
●Percentage of 
“off” time from 
baseline to end 
point  
●On time with 
dyskinesia 
●On time 
without 
dyskinesia 
●UPDRS scores 
●CGI-I scores  
●Adverse events 
Hauser et al 
(2008) 
6002-US-013 
Study 
USA 
[63] 
●Phase III 
●Multicentric 
double-blind, 
placebo-
controlled  
randomised trial 
(randomisation 
ratio 1:1) 
231 subjects 
with  LD treated 
PD who have 
motor 
fluctuations 
  
●Istradefylline 
20 mg per day 
oral vs. placebo 
→12 weeks 
 
 
 
●Percentage of 
“off” time from 
baseline to end 
point.  
●On time with 
dyskinesia 
●On time 
without 
dyskinesia 
●UPDRS scores 
●CGI-S scores 
●PGI-I scores  
●Adverse events 
Stacy et al. 
(2008) 
6002-US-006 
Study 
USA 
[64] 
 
●Phase III 
●Multicentric 
double-blind, 
placebo-
controlled,  
randomised  
trial  
(randomisation 
ratio 1:2:2) 
395 subjects 
with  LD treated 
PD who have 
motor 
fluctuations  
●Istradefylline 
20 mg per day 
oral vs. placebo 
●Istradefylline 
40 mg per day 
oral vs. placebo  
→12 week  
●Percentage of 
“off” time from 
baseline to end 
point. 
●On time with 
dyskinesia 
●On time 
without 
dyskinesia 
●UPDRS scores 
●CGI-S scores 
●Adverse events 
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Fernández et al 
(2010) 
6002-US-051 
trial 
USA 
[66] 
●Phase II  
●Multicentric 
double-blind, 
placebo-
controlled 
randomised trial 
(randomisation 
ratio 1:1) 
197 patients 
without  
treatment with 
dopaminergic 
agents or LD 
●Istradefylline 
40 mg per day 
oral vs. placebo 
→12 week  
●Change from 
baseline at 
endpoint in the 
UPDRS part III 
subscale score 
 
●UPDRS 
subscale I, II, 
IVA scores 
●UPDRS total 
score 
●WPI score  
●PGI-I score  
●CVLT score 
●VFT score  
●Adverse events 
Mizuno et al 
(2010) 
The Japanase 
Istradefylline 
Sudy 
Japan 
[65] 
●Phase III 
●Mulicentric 
double-blind, 
placebo-
controlled 
randomised trial 
(assigned by 
1:1:1 
randomisation 
ratio) 
363 patients 
with LD treated 
PD who have 
motor 
fluctuations 
●Istradefylline 
20 mg per day 
oral vs. placebo 
●Istradefylline 
40 mg per day 
oral vs. placebo 
→12 week  
●Change in  
daily off time 
from baseline at 
endpoint 
 
●On time with 
dyskinesia 
●UPDRS part 
III subscale 
score  
●CGI-I score 
●Adverse events 
UPDRS: Unified Parkinson’s Disease Rating Scale; CGI-I: Clinical Global Impression-Improvement scale; CGI-
S: Clinical Global Impression-Severity of Illness scale; PGI-I: Patient Global Impression-Improvement scale; 
WPI: Webster Performance Index; CVLT: California Verbal Learning Test; VFT: Verbal FluencyTest. 
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Table 2. Baseline demographic and disease characteristics of the patients. 
 
 Bara-Jimenez 
2003 
Hauser  
2003 
LeWitt 
2008 
Hauser 
2008 
Stacy 
2008 
Fernández
2010 
Mizuno 
2010 
Age 63 64 63 63 63-65 63 65 
Gender male% 53% 57% 60% 66% 64-68% 60% 43,5-44% 
Duration of  
illness and symptoms 
       
Mean time since  
diagnosis of PD 
8.1 years NR 9.3 years 10 years 3 years 1.4 years 8 years 
Mean time since onset  
of motor complications 
NR NR 3.3 years 4 years NR NR 3 years 
Mean time spent 
 in the OFF state 
NR 6 hours 6 hours 6.7 hours 5.7 hours - 6 hours 
Mean time ON state  
without dyskinesia 
NR NR 7.3 hours 7.3 hours 7-8 hours - NR 
Mean time ON state  
with dyskinesia, mean 
NR 5.1 hours 2.9 hours 2.8 hours 3-4 hours - NR 
Mean time ON state with  
troublesome  dyskinesia 
NR NR 0.6 hours 0.7 hours 0.6-1 hours - NR 
Mean time ON state  
without troublesome  
dyskinesia 
NR NR 9.5 hours 9.4 hours 10 hours - NR 
Clinical Rating scales  
of the disease 
       
UPDRS Part II  
subscale score 
NR NR 6.4 6.8 6-7 8.2 NR 
UPDRS Part III subscale  
score (on-state), mean 
NR 18.2 17.7 23.9 17-18 20.6 21 
Concomitant medications        
L-DOPA % 100% 100% 100% 100% 100% 0 100% 
Daily dosage of L-DOPA 857 mg 818 mg 560 mg 652 mg NR - 400 mg 
Dopamine agonists NR 52% 89,9% 4%-42% 91% - 92-96% 
Selegiline NR 22.2% 18.6% 11.3% 15-16% - 50-54% 
Entacapone NR 29.6% 41.1% 47.8% 41-44% - 13-19% 
Amantadine NR NR 27.1% 32.2% 26-28% - 31.5-37% 
Other NR NR NR 9%-42% 20-40% - 16-18% 
UPDRS: Unified Parkinson Disease Rating Scale; NR: Not reported. 
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 Table 3. Efficacy results. Change in outcomes from baseline to end point 
 
Time spent in the OFF stat
Mean Change  
UPDRS subscale III 
On state 
 
 
Study 
 
% Hours LS mean change LS mean difference
 from placebo 
Hauser 2003 
stradefylline 5/10/20 mg/day -8.2* -1.4* NR NR 
stradefylline 5/10/20 mg/day -6.1* -1.1* NR NR 
Placebo 2.2 0.5   
LeWitt 2008 
Istradefylline 40 mg/day -10.81*  -1.79*  -0.4 NR 
Placebo -4.04 -0.64 -0.2  
Hauser 2008     
Istradefylline 20 mg/day -9.3*  -1.6* NR NR 
Placebo -5.0  -0.9  NR  
Stacy 2008     
Istradefylline 20 mg/day -7.83 * -1.24  NR -0.30 
Istradefylline 60 mg/day -7.96* -1.37 NR -0.87 
Placebo -3.47 -0.60 NR  
Fernández 2010    
Istradefylline 40 mg/day NR NR -0.74 -1.11 
Placebo NR NR 0.36  
Mizuno 2010    
Istradefylline 20 mg/day NR -1.31*  -1.31* -2.0* 
Istradefylline 40 mg/day NR -1.58*  -1.58* -2.0* 
Placebo NR -0.66 -0.66  
*P‐value<0.05 when compared with placebo; LS Least Square; NR Not reported. 
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Table 4. Most frequent adverse events possible or probably related to study 
reported by 5% or more subjects in either treatment group, by system organ class 
and preferred term (safety population) 
 
MedDRA System Organ 
Class/  
Preferred term 
Istradefylline 
(N = 953) n (%) 
Placebo 
(N =488) n (%) 
Nervous system disorders   
Dyskinesia 166 (17.4) 42 (8.6) 
Dizziness 60 (6.3) 13 (2.7) 
Lightheadedness 17 (1.8) 8 (1.6) 
Dizziness postural 11 (1.1) 1 (0.2) 
Headache 11 (1.1) 4 (0.8) 
Gastrointestinal disorders   
Nausea 101 (10.6) 28 (5.7) 
Constipation 47 (4.9) 18 (3.7) 
Diarrhoea  11 (1.1) 10 (2.0) 
Psychiatric disorders   
Hallucinations 27 (2.8) 5 (1.0) 
Insomnia 27 (2.8) 17 (3.5) 
Respiratory, thoracic and 
mediastinal disorders 
  
Nasopharyngitis 22 (2.3) 6 (1.2) 
Upper respiratory tract 
inflammation 
11 (1.1) 1 (0.2) 
Upper respiratory tract 
infection 
10 (1.0) 3 (0.6) 
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 Table 5. Ongoing clinical trials testing drugs acting on A2R registered with 
www.ClinicalTrials.gov (on March 30, 2011). 
 
ID Sponsor Status Design/ 
Clinical 
trial  
Phase 
Experimental 
Drug / 
Duration 
 
Control 
 
Size 
(n) 
Condition PD 
NCT00955526 Kyowa 
Hakko 
Kirin 
A 
(ESCD 
May 2011) 
DB RCT 
Phase III 
●Istradefylline 
20 and 40 
mg/day / 12-
weeks 
-Placebo 360 UKPDS step 1-2 
MHYS stages 2-4 
off state 
On LD/DC 1year 
NCT00957203 Kyowa 
Hakko 
Kirin 
A 
(ESCD 
June 2012) 
OL 
NRCT 
SG 
Phase III 
●Istradefylline 
20 and 40 
mg/day / long-
term 
- 150 Advanced PD 
treated with LD 
NCT01155479 Schering-
Plough 
(P05664AM2)
R 
(June 
2013) 
DB RCT 
Phase III 
●Preladenant 
4, 10, 20 mg 
daily / 
52 weeks 
-Placebo 
(26 weeks) 
and after 
Preladenant 
(26 weeks) 
-Rasagiline 
1mg daily 
1,000 -PD < 5 years 
-UKPDS Part III 
≥ 10 
-HYS stage ≤ 3 
NCT01227265 Schering-
Plough 
(P07037AM1)
R 
(September 
2012) 
DB RCT 
Phase III 
●Preladenant   
4, 10, 20 mg 
daily/  
12 weeks  
-Placebo 450 -On LD≥1 year  
-HYS 2.5-4 “on” 
state 
- ≥ 2 hours day 
“off” time 
NCT01155466 Schering-
Plough 
(P04938AM3)
R 
 (February 
2013) 
DB RCT 
Phase III 
●Preladenant   
4, 10, 20 mg 
daily/  
12 weeks 
- Placebo 
- Rasigiline 
1mg daily 
750 -On LD≥1 year  
-HYS 2.5-4 “on” 
state 
- ≥ 2 hours day 
“off” time 
NCT01294800 Schering-
Plough 
(P06402) 
R 
(June 
2013) 
DB RCT 
Phase III 
●Preladenant   
4, 10, 20 mg 
daily/  
12 weeks 
- Placebo 440 -On LD≥1 year  
-HYS 2.5-4 “on” 
state 
- ≥ 2 hours day 
“off” time 
NCT01215227 Schering-
Plough 
(P06153AM1)
R 
(January 
2013) 
DB RCT 
Phase III 
●Preladenant   
4, 10, 20 mg 
daily/  
40 weeks 
- Placebo 
- Rasigiline 
1mg daily 
750 -On LD≥1 year  
-HYS 2.5-4 “on” 
state 
- ≥ 2 hours day 
“off” time 
NCT00406029 Schering-
Plough 
(P04501AM3)
C DB RCT 
Phase II 
●Preladenant   
2, 4, 10 mg 
daily/  
12 weeks 
- Placebo 200 PD moderate to 
severe ≥ 5 years 
NCT00537017 Schering-
Plough 
(P05175AM1)
C OL, SG 
NRCT 
Phase II 
●Preladenant   
10 mg daily/  
12 weeks 
- 200 PD moderate to 
severe ≥ 5 years 
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NCT01323855 Schering-
Plough 
(P06512AM1)
NYR 
(September 
2011) 
OL, SG 
NRCT 
Phase I 
●Preladenant   
5 mg daily/  
 72 hours 
- 54 Mild to severe 
chronic renal 
impairment   
NCT00845000 Schering-
Plough 
(P05550AM2)
C SB RCT 
Phase II 
●Preladenant 
10 or 100 mg 
daily and LD 
intravenous 
and oral 
carbidopa/ 5 
hours 
- Placebo 18 -On LD≥1 year  
- Motor 
fluctuations and 
UPDRS 
20%improvement 
when “on” 
- Dyskinesia 
when “on” ≥ 2 on 
scale (0-4) 
NCT00442780 Biogen IDEC C DB RCT 
Phase II 
●BIIB014 
dose 
escalation /NR 
Placebo 36 PD  ≤ 5 years 
MHYS stages 1-
2.5 
NCT00438607 Biogen IDEC C DB RCT 
Phase II 
●BIIB014  
escalation /NR 
Placebo 83 MHYS stages 2-4 
off state 
NCT00451815 Biogen IDEC W DB RCT 
Phase II 
●BIIB014  
10,30, 100, 
300 mg once 
daily 
Placebo NR MHYS stages 1-3
NCT01283594 
 
Synosia 
Therapeutics 
NYR 
(August 
2012) 
DB RCT 
Phase 
II/III 
●SYN115 60, 
120, 180, 140 
mg / NR 
Placebo 400 PD with good 
response LD 
NCT00605553 Synosia 
Therapeutics 
C DB 
Crossover 
RCT 
Phase II 
●SYN115  
20, 60 mg 
daily / 1 week 
Placebo 30 MHYS stages 1-3
ID: ClinicalTrials.gov Identifier; Size (n): estimated enrolment of the number of patients; PD: Parkinson 
Disease; Status: C (Completed) the study has been completed, A (Active) the study is ongoing, but not 
recruiting participants, R (Recruiting) the study is currently recruiting participants, W (Withdrawn) the study 
has been withdrawn prior enrollment of patients, NYT The study is not yet open for participant recruitment.; 
ESCD: Estimated Study Completion Data; DB: Double blind masking; OL: Open label masking; SB: Single 
blind masking; SG: Single group; RCT: randomised clinical trial; NRCT: nonrandomised clinical trial; 
UKPDS: UK Parkinson's Disease Society (UKPDS) criteria for PD; HYS: Hoehn and Yahr Scale; MHYS: 
Modified Hoehn and Yahr Scale: LD: L-DOPA; NR: Non reported. 
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